8Suppliers
15Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Taysha Gene Therapies, Inc. (TSHA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

27Total relationships
3Distinct source URLs
11High confidence
0.736Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Taysha Gene Therapies, Inc. Suppliers

TickerNameConfidenceEvidence
ASTELLAS ASTELLAS 90% As further consideration for the rights granted to Astellas under the Option Agreement, the Company and Astellas also entered into the Astellas Securities Purchase Agreement
AUDENTES-THERAPEUTICS-INC-D-B-A-ASTELLAS-GENE-TH AUDENTES-THERAPEUTICS-INC-D-B-A-ASTELLAS-GENE-TH 90% the option agreement dated October 21, 2022, or the Option Agreement, with Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy), or Astellas
THE-UNIVERSITY-OF-TEXAS-SOUTHWESTERN-MEDICAL-CEN THE-UNIVERSITY-OF-TEXAS-SOUTHWESTERN-MEDICAL-CEN 90% In connection with the UT Southwestern Agreement, we obtained an exclusive, worldwide, royalty-free license under certain patent rights of UT Southwestern
SSI SSI 85% SSI provides certain consulting services to the Company
ABEONA-THERAPEUTICS-INC ABEONA-THERAPEUTICS-INC 80% pursuant to which we obtained an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses under certain patents, know-how and materials originally developed by the Universit…
SILICON-VALLEY-BANK SILICON-VALLEY-BANK 80% from our previous loan agreement with Silicon Valley Bank
TRINITY-CAPITAL TRINITY-CAPITAL 80% from our current loan agreement with Trinity Capital
RGNX REGENXBIO Inc. 72% Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that …

Taysha Gene Therapies, Inc. Customers

TickerNameConfidenceEvidence
RGNX REGENXBIO Inc. 72% Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that …
TRIN Trinity Capital Inc. 72% Reciprocal relationship from TRIN graph: Reciprocal relationship from TSHA graph: Reciprocal relationship from TRIN graph: Reciprocal relationship from TSHA graph: e and next-generation platforms; • …
TRIN Trinity Capital Inc. 72% e and next-generation platforms; • scale up our clinical and regulatory capabilities; • manufacture current good manufacturing practice, or cGMP, material for clinical trials or potential commercial …
AUDENTES-THERAPEUTICS-INC AUDENTES-THERAPEUTICS-INC 62% to continue to incur significant expenses and operating losses for the foreseeable future. Our net losses were $89.3 million and $111.6 million for the years ended December 31, 2024 and 2023, respect…
BARCLAYS-CAPITAL-INC BARCLAYS-CAPITAL-INC 62% lected the fair value option for the 2025 Trinity Term Loan and changes to fair value, other than changes that are directly attributed to instrument-specific credit risk, were recorded as a component…
BCS Barclays PLC 62% Reciprocal relationship from BCS graph: Reciprocal relationship from TSHA graph: lected the fair value option for the 2025 Trinity Term Loan and changes to fair value, other than changes that are dir…
CO-LLC CO-LLC 62% ling $1.4 million for the year ended December 31, 2023 due to the early payoff of the Term Loan with Silicon Valley Bank in November 2023. Interest income Interest income was $6.9 million for the yea…
EMERGING-GROWTH-COMPANY EMERGING-GROWTH-COMPANY 62% . The Trinity Term Loans contains various embedded features and the election of the fair value option allows us to bypass analysis of potential embedded derivatives and further analysis of bifurcatio…
JEFFERIES-LLC-BOFA-SECURITIES-INC JEFFERIES-LLC-BOFA-SECURITIES-INC 62% lected the fair value option for the 2025 Trinity Term Loan and changes to fair value, other than changes that are directly attributed to instrument-specific credit risk, were recorded as a component…
PEGASUS-PARK-LLC PEGASUS-PARK-LLC 62% ame currency, for a similar term, in a similar economic environment. To estimate its incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating…
SMALLER-REPORTING-COMPANY SMALLER-REPORTING-COMPANY 62% . The Trinity Term Loans contains various embedded features and the election of the fair value option allows us to bypass analysis of potential embedded derivatives and further analysis of bifurcatio…
SSI-STRATEGY-HOLDINGS-LLC SSI-STRATEGY-HOLDINGS-LLC 62% ling $1.4 million for the year ended December 31, 2023 due to the early payoff of the Term Loan with Silicon Valley Bank in November 2023. Interest income Interest income was $6.9 million for the yea…
SVB-LEERINK-LLC SVB-LEERINK-LLC 62% ling $1.4 million for the year ended December 31, 2023 due to the early payoff of the Term Loan with Silicon Valley Bank in November 2023. Interest income Interest income was $6.9 million for the yea…
SVB-SECURITIES-LLC SVB-SECURITIES-LLC 62% , therefore the change in fair value of warrant liability was zero for the three months ended March 31, 2026. Change in fair value of term loan We elected the fair value option for the 2025 Trinity T…
WELLS-FARGO-SECURITIES-LLC WELLS-FARGO-SECURITIES-LLC 62% ling $1.4 million for the year ended December 31, 2023 due to the early payoff of the Term Loan with Silicon Valley Bank in November 2023. Interest income Interest income was $6.9 million for the yea…

Taysha Gene Therapies, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
TSHA-DEBT-13123 Xbrl Convertible 90% xbrl convertible detail from xbrl 2020-12-31.
TSHA-DEBT-13122 Warrants outstanding: 1637000 90% xbrl warrant detail from xbrl 2025-12-31.
TSHA-DEBT Debt stack $49.3M 90% Market cache reports total debt of $49.3M.

Taysha Gene Therapies, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Taysha Gene Therapies, Inc..

Taysha Gene Therapies, Inc. Ownership

HolderNameConfidenceEvidence
TSHA-OWNER-MORGAN-STANLEY MORGAN STANLEY 90% 13F overlay lists MORGAN STANLEY as top holder; 195 tracked holders.

Taysha Gene Therapies, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
BCS Barclays PLC 100.00 1 ['customer']
RGNX REGENXBIO Inc. 100.00 1 ['customer', 'supplier']
RPID Rapid Micro Biosystems, Inc. 100.00 2
CADL Candel Therapeutics, Inc. 100.00 2
SI Shoulder Innovations, Inc. 100.00 2
CORZ Core Scientific, Inc. 50.00 2
REGN Regeneron Pharmaceuticals, Inc. 50.00 2
CGBD Carlyle Secured Lending, Inc. 50.00 2
ABBV AbbVie Inc. 50.00 2
BP BP p.l.c. 50.00 2
CHWY Chewy, Inc. 50.00 2
FDMT 4D Molecular Therapeutics, Inc. 50.00 2
GEVO Gevo, Inc. 50.00 2
OTLK Outlook Therapeutics, Inc. 50.00 2
FBRT Franklin BSP Realty Trust, Inc. 50.00 2
DNLI Denali Therapeutics Inc. 50.00 2
TNYA Tenaya Therapeutics, Inc. 50.00 2
KVAC Keen Vision Acquisition Corporation 50.00 2
SRPT Sarepta Therapeutics, Inc. 50.00 2
STEM Stem, Inc. 50.00 2
🔐
TSHA
Unlock TSHA Supply Chain Data
Verified relationships include:
ASTELLASASTELLASSupplier90%
AUDENTES-THERAPEUTICS-INC-D-B-A-ASTELLAS-GENE-THAUDENTES-THERAPEUTICS-INC…Supplier90%
RGNXREGENXBIO Inc.Customer72%
TRINTrinity Capital Inc.Customer72%
+23 more relationships locked
Subscribe — View plans →